[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352066-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352066-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","lactate-dehydrogenase-to-lymphocyte-ratio-predicts-overall-and-progression-free-survival-among-patients-with-advanced-small-cell-lung-cancer-receiving-first-line-chemoimmunotherapy-a-two-center-retrospective-observational-study","Lactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy - A two-center retrospective observational study","","Platinum plus etoposide combined with PD-L1 inhibitors is standard first-line therapy for extensive-stage small-cell lung cancer, yet reliable prognostic biomarkers remain limited. A retrospective two-center study in Japan evaluated whether the lactate dehydrogenase-to-lymphocyte ratio (LLR) predicts overall survival (OS) and progression-free survival (PFS) in patients receiving first-line chemoimmunotherapy. Sixty-four patients were analyzed using X-tile cutoff values and survival modeling. High LLR independently predicted worse OS and PFS and outperformed NLR and PLR for PFS. Because LLR is calculated from routine blood tests, it may enable cost-effective risk stratification, pending prospective validation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/lactate-dehydrogenase-to-lymphocyte-ratio-predicts-overall-and-progression-free-survival-among-patients-with-advanced-small-cell-lung-cancer-receiving-first-line-chemoimmunotherapy-a-two-center-retrospective-observational-study/352066/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/lactate-dehydrogenase-to-lymphocyte-ratio-predicts-overall-and-progression-free-survival-among-patients-with-advanced-small-cell-lung-cancer-receiving-first-line-chemoimmunotherapy-a-two-center-retrospective-observational-study/352066.png","ImageObject",300,407,{"name":42,"@type":43},"nayy☆","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What biomarker did the study evaluate in advanced small-cell lung cancer?","Question",{"text":63,"@type":64},"The study evaluated the lactate dehydrogenase-to-lymphocyte ratio (LLR) as a potential prognostic biomarker in patients receiving first-line chemoimmunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the LLR measured and categorized?",{"text":68,"@type":64},"LLR was calculated from blood tests taken immediately before starting first-line therapy. Cutoff values were determined using X-tile software.",{"name":70,"@type":61,"acceptedAnswer":71},"What was the relationship between high LLR and survival outcomes?",{"text":72,"@type":64},"High LLR was significantly associated with shorter overall survival and progression-free survival, and it remained an independent predictor in multivariate analyses.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352066,1790399826,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},962090893153,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","®  \n Observational Study   \nLactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy A two-center retrospective observational study  \nTomofumi Hirose, MDa , Shuhei Teranishi, MD, PhDb ,* , Nobuaki Kobayashi, MD, PhDc , Anna Tanaka, MDa , Yukihito Kajita, MDc , Ayami Kaneko, MD, PhDc , Masaki Yamamoto, MD, PhDa , Makoto Kudo, MD, PhDa , Takeshi Kaneko, MD, PhDc  \n\n| Abstract\u003Cbr>Platinum plus etoposide combined with programmed death-ligand 1 (PD-L1) inhibitors is the standard first-line therapy for patients with advanced small-cell lung cancer (SCLC) . However, reliable prognostic biomarkers are yet to be identified. The lactate dehydrogenaseto-lymphocyte ratio (LLR) is a potential indicator of tumor metabolism and host immune response; a high LLR is correlated with a poor prognosis in other carcinomas. The LLR may be a more comprehensive indicator of prognosis than the neutrophil-lymphocyte ratio (NLR) or platelet-lymphocyte ratio (PLR), which mainly reflect host immune status. This study evaluates the prognostic value of the LLR in patients with SCLC receiving first-line chemoimmunotherapy. This retrospective, two-center study was conducted at 2 university hospitals in Japan and analyzed 64 patients with extensive-stage SCLC or post-chemoradiotherapy recurrence of limitedstage SCLC who received platinum-etoposide plus a PD-L1 inhibitor as first-line therapy between August 2019 and December 2023. The LLR, NLR, and PLR were calculated from blood tests immediately before the start of first-line therapy, and cutoff values were set using the X-tile software. The prognostic significance of these markers was assessed using Kaplan–Meier survival analysis and the Cox proportional hazards model. Of the 64 patients included, 10 (16%) had high LLR (>471 .5) . The median duration of observation was 10.5 months (interquartile range: 6.0–19.0 months); by the time of data cutoff, 56 patients (87 .5%) had experienced progressive disease and 36 (56 .3%) had died. The high LLR group had significantly shorter overall survival (OS) and progression-free survival (PFS) . Multivariate analysis was performed using only those factors (LLR/ECOG PS/bone metastasis regarding OS and LLR/bone metastasis regarding PFS) identified as significant in univariate analyses. A high LLR was an independent predictor of worse OS and PFS. While the NLR was an independent prognostic factor for OS, neither NLR nor PLR was a significant predictor of PFS. The LLRis a novel potential prognostic biomarker that integrates tumor metabolism and host immunity in patients with SCLC receiving firstline chemoimmunotherapy. Because it can be readily calculated from routine blood tests, it may serve as a cost-effective tool for risk stratification. However, further prospective validation in larger cohorts is warranted. |\n| --- |\n| Abbreviations: CI = confidence interval, DCR = disease control rate, ECOG PS = Eastern Cooperative Oncology Group Performance Status, ES-SCLC = extensive-stage small-cell lung cancer, HR = hazard ratio, LDH = lactate dehydrogenase, LLR = lactate dehydrogenase-to-lymphocyte ratio, LS-SCLC = limited-stage small-cell lung cancer, NLR = neutrophil-to-lymphocyte ratio, ORR = objective response rate, OS = overall survival, PD = progressive disease, PD-L1 = programmed death-ligand 1, PFS = progression-free survival, PLR = platelet-to-lymphocyte ratio, RECIST = Response Evaluation Criteria in Solid Tumors, SCLC = small-cell lung cancer. |\n| Keywords: immune checkpoint inhibitor, lactate dehydrogenase-to-lymphocyte ratio, overall survival, progression-free survival, small-cell lung cancer |\n\nThis study was retrospective in nature and did not require written informed consent from the patients. Instead, we published the study information on the hospital’s website and offered patients the option to refuse to participate. The authors have no fundin","cbCaiatLytUdkEkk","https://ap.wps.com/l/cbCaiatLytUdkEkk","pdf",1447354,"English","# Introduction\n# Methods\n## Study design and population\n## Biomarker calculation and cutoffs\n## Survival analyses\n# Results\n## Patient characteristics and marker distributions\n## Association with OS and PFS\n## Multivariate analysis\n# Discussion\n# Conclusions","[{\"question\":\"What biomarker did the study evaluate in advanced small-cell lung cancer?\",\"answer\":\"The study evaluated the lactate dehydrogenase-to-lymphocyte ratio (LLR) as a potential prognostic biomarker in patients receiving first-line chemoimmunotherapy.\"},{\"question\":\"How was the LLR measured and categorized?\",\"answer\":\"LLR was calculated from blood tests taken immediately before starting first-line therapy. Cutoff values were determined using X-tile software.\"},{\"question\":\"What was the relationship between high LLR and survival outcomes?\",\"answer\":\"High LLR was significantly associated with shorter overall survival and progression-free survival, and it remained an independent predictor in multivariate analyses.\"}]","Lactate dehydrogenase-to-lymphocyte ratio predicts overall and progression-free survival among patients with advanced small-cell lung cancer receiving first-line chemoimmunotherapy - A two-center retrospective observational study | PDF",1790097524,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52fe52bc79d0ef812d01039580b9491b.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33b481202dd5e94d214723905d37b346.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93b4d34b10ed77f178efa8c033ed64fa.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5b4539b33ead99e6e0bb8ef2abf4ec7a.webp",980,1306]